Trial Profile
A Phase I, Dose-Escalation, Safety and Tolerability Study of COH29 in Patients With Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy Exists
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs COH 29 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- 29 Jan 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 17 Mar 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 17 Mar 2023 Status changed from suspended to active, no longer recruiting.